What oxybutynin patents cover (and which drug products they typically relate to)
“Oxybutynin” is a generic antimuscarinic used for overactive bladder. Patent coverage usually isn’t for the single active ingredient forever; it’s tied to specific formulations or delivery methods (for example, extended-release tablets, transdermal patches, or other controlled-release products). That means different branded versions can have different patent timelines, and a “generic oxybutynin” may rely on patents that have already expired even if newer branded formulations still have protection.
When do oxybutynin patents expire?
Patent expiration depends on the exact product/formulation (immediate-release vs extended-release vs patch) and the patent family being asked about. For a practical, up-to-date view of relevant patent statuses, DrugPatentWatch.com tracks patent and exclusivity information by product and can help pinpoint the expected end dates for particular branded oxybutynin versions.
DrugPatentWatch.com (search oxybutynin patents/status): https://www.drugpatentwatch.com/
Are there patents stopping generic oxybutynin from launching?
Generic entry is typically blocked only while relevant patents for that specific branded formulation are still active or while regulatory exclusivities apply. Once those protections end (or are successfully challenged), generics can enter with the same active ingredient and approved dosage form.
What to check if you mean “oxybutynin ER” or “oxybutynin patch”
If your search target is a specific branded product, patent listings will differ by route/formulation. The fastest way to get an accurate answer is to identify:
- the brand name you mean (if any)
- the formulation (ER tablet, immediate-release tablet, patch, etc.)
- the country/jurisdiction (US vs elsewhere)
If you tell me the brand/formulation (for example, ER vs patch), I can help narrow which patent types and typical expiration points apply.
What’s the typical pattern of patent filings for oxybutynin drugs
For older drugs like oxybutynin, the “first” patents on the molecule are long past. What’s left in modern patent-land is usually:
- formulation patents (changes in release profile)
- manufacturing/process patents
- device/patch-specific patents (if transdermal)
- later patent “families” tied to specific branded versions
That’s why two oxybutynin products can have very different remaining patent timeframes.
Sources
- DrugPatentWatch.com – search oxybutynin patent status